The impact of donor-recipient ABO incompatibility on long-term BMT outcomes remains controversial. A common strategy is to deplete the donor marrow of red cells, although this variably reduces the number of CD34 þ cells. This 10-year retrospective study assessed the impact of recipient plasma exchange in major ABO-incompatible allogeneic BMT on outcomes and survival. Target Ab titres werep1:4 for anti-A andp1:8 for anti-B. Patients with higher titres underwent plasma exchange before marrow infusion. Of 133 patients who underwent allogeneic BMT, 34 had a major ABO-incompatible donor. The median number of exchanges was 2 (range 1-4). There were no acute haemolytic transfusion reactions. Engraftment times, transfusion requirements and acute and chronic GVHD were no different from those of patients with an ABO-identical donor. Treatment-related mortality at 100 days was 21% in the group with a major ABO-incompatible donor and 17% in the group with an identical donor (P ¼ 0.8). Plasma exchange of the recipient is a safe method of managing donor-recipient major ABO incompatibility before BMT without the risk of haematopoietic progenitor cell loss associated with red cell depletion of the graft.
INTRODUCTION
Major ABO blood group incompatibility, in which the recipient has isohemagglutinins directed against donor red cells is present in approximately 25% of all haematopoietic progenitor cell transplants. 1 When BM is used as the source of progenitor cells, red cells may constitute 25-35% of the unmanipulated product volume. 2 Without intervention, the infusion of such a large red cell volume along with the progenitor cell product may lead to acute haemolysis or other complications, such as delayed red cell engraftment or pure red cell aplasia (PRCA). 3, 4 The literature provides inconsistent conclusions about the effect of donor-recipient ABO incompatibility on haematopoietic progenitor cell transplant outcomes. Some authors have reported adverse short-term effects, including increased time to engraftment 5, 6 and increased transfusion requirements. 7 Others have reported long-term consequences of increased incidence of graft failure, 8 increased GVHD and treatment-related mortality (TRM) 9 and poorer OS. 5, 10 Conversely, some have found that ABO incompatibility has no significant impact on these outcomes. [11] [12] [13] The variability in reported outcomes may reflect differences in patient populations, progenitor cell source, conditioning and GVHD-prophylaxis. In addition, there is no current consensus on the best management of donor-recipient ABO incompatibility. Many groups deplete the progenitor cell product of red cells. However, even using modern apheresis techniques, this results in the recovery of only 10-60% of the total nucleated cells. 2 Furthermore, the manipulated product generally still contains 5-40 mL of red cells, 2, 14 although a volume that is generally agreed to be safe to infuse has not been defined. An alternative approach is to reduce the recipient's isohemagglutinin titre through plasma exchange, replacing with AB plasma or albumin; column immunoadsorption; or in vivo immunoadsorption using donor ABO-incompatible red cells. [15] [16] [17] [18] There is no consensus on the best method of managing ABOincompatible BMT. 18 The most commonly used strategy is red cell depletion. Herein, we report on the safety of recipient plasma exchange without graft manipulation, for the management of ABO-incompatible BMT at a single institution.
MATERIALS AND METHODS
All major ABO-incompatible BMTs performed at the Ottawa Hospital over a 10-year period between January 2000 and December 2010 were identified from the Blood and Marrow Transplant Database. This is a prospective database that includes records of any adverse event, including infusionrelated reactions, collected at the time of marrow infusion. Any event considered at least minor, for example, hives, fever, volume overload, would be captured in the database. Detailed information about the subsequent post-transplant course is obtained by a review of each patient's chart. Information was obtained from the database as well as, when necessary, review of individual patient medical records.
Outcomes
The primary outcome was the incidence of major haemolytic transfusion reactions. Secondary outcomes included: the proportion of patients in whom the target isohemagglutinin titre was achieved; incidence of grades 2-4 acute GVHD at 100 days; incidence of chronic GVHD, reported for patients surviving at least 100 days; time to neutrophil engraftment, defined as a neutrophil count40.5 Â 10 9 /L; time to platelet engraftment, defined as a platelet count420 Â 10 9 /L with no platelet transfusions for 3 days; red cell transfusion requirements over the 6 months following the marrow infusion; incidence of PRCA; 100-day TRM, defined as death in the absence of underlying disease within the first 100 days; and OS. Results were compared with a group of patients undergoing transplantation with an ABO-identical donor during the same time period.
Isohemagglutinin titre measurement
Isohemagglutinin titres were determined by testing serial dilutions of the patients' plasma against a constant volume of red cells. The result was expressed as a reciprocal of the highest dilation at which macroscopic agglutinin of 1 þ strength was observed. 19 
Plasma exchange
Target Ab titres werep1:4 for anti-A, andp1:8 for anti-B. All patients with isohemagglutinin titres above target received single-volume plasma exchange through a peripheral i.v. catheter 1-3 days before the graft infusion using the COBE Spectra Apheresis System (CaridianBCT, Lakewood, CO, USA). Replacement fluid was 5% albumin in normal saline. Isohemagglutinin titres were measured before and after each exchange to determine the need for additional exchanges.
Red cell depletion
Red cell reduction was achieved by first adding hydroxyethyl starch to the marrow graft. After 1 h had passed, for sedimentation of the red cells, they were manually removed, leaving behind the buffy coat. 20 Statistical analysis Baseline characteristics were described using measures of central tendency and dispersion where appropriate. Outcomes of patients with major ABO incompatibility were compared with a larger cohort of patients who underwent BMT during the same time period with an ABO-identical donor. Fisher's exact test was used to compare proportions in each group developing acute haemolysis, acute and chronic GVHD, PRCA and 100-day TRM. Times to engraftment and transfusion requirements were analysed using Student's t-test. OS was estimated using the Kaplan-Meier method.
RESULTS
Of the 133 patients who underwent allogeneic BMT using a marrow-derived graft, between January 2000 and December 2010, there were 34 with major donor-recipient ABO incompatibility. Baseline characteristics are shown in Table 1 . There were 24 type O patients with type A donors, 5 type O patients with type B donors, 3 type A patients with AB donors and 2 type O patients with AB donors. All patients received non-T-cell-depleted BM as a stem cell source. The median total nucleated cell was 2.7 (1.4-5.2) Â 10 8 /kg in the patients undergoing BMT with a major ABOincompatible graft and 2.8 (1.2-9.5) Â 10 8 /kg in those with an ABO-identical graft. Of the major ABO-incompatible transplants, there was a one-Ag donor-recipient HLA mismatch in one related donor and one unrelated donor BMT. Of the ABO-identical transplants, there was a one-Ag mismatch in two related donors and one unrelated donor. Rabbit anti-thymocyte globulin was given to all patients receiving a marrow graft from an unrelated donor. Short-course MTX and a calcineurin inhibitor were used for GVHD prophylaxis. The median follow-up time for the whole cohort was 17 (range 0-133) months.
Haemolysis
There were no cases of clinically significant acute or subacute haemolysis associated with infusion of the marrow graft.
Plasma exchange Initial isohemagglutinin titres and response to plasma exchange for all 34 patients with major ABO incompatibility are shown in Table 2 . Eight patients did not require plasma exchange because their baseline titre was at or below the target. In the 26 patients who underwent exchange, the median number of exchanges required was 2 (range 1-4). In all, 11 patients had 1 exchange, 9 patients had 2 exchanges, 3 patients had 3 and 3 patients had 4.
One patient (patient 19) underwent exchange despite having an initial titre of 1:2 for unclear reasons. The median titre level before plasma exchange was 1:16 (1:1-1:2048). The median final titre was 1:4 (1:1-1:128).
There were nine patients in whom the target titre of 1:4 or 1:8 was not achieved following plasma exchange. In two of these patients, the graft was red cell reduced. Patient 25 was type O and had an AB donor. The initial anti-A titre was 1:256 and the anti-B titre was 1:1024. Following four exchanges, the anti-A and anti-B titres were 1:128 and 1:16, respectively. The decision was made to reduce the red cell content of the graft. The number of CD34 þ cells decreased from 3.28 to 3.21 Â 10 6 /kg following red cell reduction. The final red cell content of the graft was 59 mL and it was infused without incident.
Patient 13 was type O and the donor was type A. After four exchanges, the anti-A titre went from 1:512 to 1:128. The original CD34 þ cell count was 2.10 Â 10 6 /kg, and fell to 2.01 Â 10 6 /kg following red cell depletion. The final volume of red cells in the graft was 60 mL. The graft was infused without incident. In the other seven patients, there was no graft manipulation. In six patients, an anti-A titre of 1:32 or less was achieved: 1:32 in two patients (patients 12 and 15), 1:16 in three patients (patients 5, 32 and 34) and 1:8 in one patient (patient 4). In one patient (patient 9), the final anti-B titre was 1:16. The grafts were infused without complication in these patients.
GVHD incidence
Two patients (5.9%) with a major ABO-incompatible graft and five of the patients (9.3%) with an ABO-identical graft developed grades 2-4 acute GVHD (P ¼ 0.70). Ten patients (29.4%) with a major incompatible graft and 16 patients (29.6%) with an ABOidentical graft developed chronic GVHD (P ¼ 1.0). 
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Engraftment
The median time to neutrophil engraftment was 22 (10-38) days in the major ABO-incompatible cohort and 21 (15-48) days in the ABO-identical cohort (P ¼ 0.83). The median time to platelet engraftment was 21 (13-99) days in the major ABO-incompatible cohort and 21 (13-158) days in the ABO-identical cohort (P ¼ 0.73).
Transfusion requirements
The median number of red cells transfused over the first 6 months post BMT was 8 (0-32) in the major ABO-incompatible group and 7 (0-70) in the ABO-identical group (P ¼ 0.62). The median number of platelets transfused over the same time period was 31 (0-245) in the major ABO-incompatible group and 30 (0-285) in the ABO-identical group (P ¼ 0.4).
Adverse events
No acute haemolytic events occurred following graft infusion. Patient 11 had a syncopal episode following the second of two exchanges. The graft was subsequently infused without incident. Patient 25, in whom anti-A and -B titres could not be reduced despite multiple exchanges and whose graft was subsequently red cell depleted, developed PRCA that occurred at day 79. The last follow-up was on day 115 and the patient died of relapsed AML shortly thereafter. Patient 13, who also had a red cell-depleted graft, died of septic shock on day 35 post transplant. Survival TRM at 100 days was 21% in the group with a major ABOincompatible donor and 17% in the group with an ABO-identical donor (P ¼ 0.8). The causes of death in the patients receiving a graft with major ABO incompatibility were: infection (n ¼ 4), acute GVHD (n ¼ 2) and secondary graft rejection without relapse (n ¼ 1). The patient who experienced graft rejection (patient 2) had not undergone plasma exchange, because of a low initial titre (1:4). In the patients receiving a graft that was ABO identical, the causes of death were: infection (n ¼ 5), treatment toxicity (n ¼ 3) and acute GVHD (n ¼ 1). At a median follow-up of 17 months survival was 38%, in the cohort undergoing major ABOincompatible BMT and 44% in the cohort undergoing BMT from an ABO-identical donor (P ¼ 0.36; Figure 1 ).
DISCUSSION
This study demonstrates that reduction of the recipient's isohemagglutinin titre by plasma exchange is a safe approach to donor-recipient ABO-incompatible BMT that spares graft manipulation and potential cell loss. In this observational study of 34 patients who underwent BMT from a major ABO-incompatible donor, there were no clinically significant haemolytic reactions on graft infusion. Furthermore, when this group of patients was compared with a group undergoing BMT from an ABO-identical Plasma exchange for ABO-incompatible BMT D Sheppard et al donor, no differences were observed in GVHD, in time to engraftment, transfusion requirements, TRM or OS. A survey of Gruppo Italiano Trapianto di Midollo Osseo centres found a high degree of heterogeneity in the methods used to address ABO-incompatible BMT. 18 In situations of major ABO incompatibility, 82.3% of centres always removed red cells from the graft, whereas 17.6% of centres decided whether red cell depletion was required based on the level of isohemagglutinin titre in the recipient. The method of red cell depletion was centre specific. Many of the centres also performed plasma exchange; 55.8% on the basis of recipient isohemagglutinin titre and 2.9% always performed plasma exchange. Certainly, the optimal method of addressing donor-recipient ABO incompatibility remains an open issue.
Although strategies used to manage donor-recipient ABO incompatibility differ between transplant centres, the most commonly used approach-particularly in North America-is red cell depletion. 18 This strategy, however, involves additional manipulation of the marrow product and may be associated with significant total nucleated cell loss. 2 This may be of particular concern if the progenitor cell content of the graft is low, potentially leading to poorer transplant outcomes.
An additional incentive to avoid manipulation of the graft stems from the fact that at our centre, the majority of BM grafts from unrelated donors comes from European centres. A prolonged interval from graft collection to infusion into the recipient has been shown to reduce the likelihood of platelet engraftment and increase mortality. 21 The strategy reported herein, recipient plasma exchange using 5% albumin in normal saline as a replacement fluid, avoids additional marrow manipulation as well as the potential complications associated with plasma infusions, including allergic reactions and transfusion-associated acute lung injury.
Centres that do not undertake pre-transplant isohemagglutinin reduction have reported most cases of PRCA post BMT. [22] [23] [24] The risk of PRCA following BMT is increased in patients with higher pre-transplant isohemagglutinin titres. 25 Furthermore, pretransplant isohemagglutinin reduction has been shown to effectively prevent PRCA. In a review of 153 patients undergoing major or bidirectional ABO-incompatible BM (74%) or peripheral blood (26%) haematopoietic progenitor cell transplant, the incidence of PRCA was 3% in the patients who underwent isohemagglutinin reduction and 16% in the patients who did not (P ¼ 0.009). 25 The results of this study are consistent with this observation. The single case of PRCA occurred in a patient with very high titres of both anti-A and anti-B, despite both isohemagglutinin reduction and red cell depletion.
This study demonstrated no differences in clinical outcomes between patients undergoing major ABO-incompatible BMT and those undergoing BMT from an ABO-identical donor. The study is limited by the fact that it is a single-centre experience with a relatively small sample size. However, the median follow-up of survivors is 17 months and, as the most significant toxicities associated with major ABO incompatibilities are infusional haemolysis and later, PRCA, the duration of follow-up is adequate to capture these events. In nine patients, the target isohemagglutinin titre was not achieved despite repeated exchanges. In two patients, the titre remained quite high (1:128) and the graft was depleted of red cells. In the remaining seven patients, the final titre was 1:32 or less. There is no isohemagglutinin titre that is universally agreed on below which complications of ABO incompatibility are unlikely. In this study, there were no adverse effects observed with anti-A titres of 1:32 or less or an anti-B titre of 1:16. It may be, that a titre 1:32 is an acceptable result of plasma exchange if performed shortly before graft infusion. It is also possible that a decrease in complement following plasma exchange contributes to its beneficial effect.
The question as to how best to manage major ABO incompatibility in BMT continues to be relevant as recent data demonstrate increased chronic GVHD in patients receiving an unrelated donor haematopoietic progenitor cell transplant using peripheral blood, as opposed to BM as the hematopoietic progenitor cell source. 26 Such data will likely result in an increase in the use of BM as a hematopoietic progenitor cell source.
In conclusion, pre-transplant recipient plasma exchange to reduce isohemagglutinin titre is a safe method of managing donor-recipient major ABO incompatibility before BMT without the risk of hematopoietic progenitor cell loss associated with red cell depletion of the graft. This has the potential for renewed importance with recent data supporting a return to BM over peripheral blood grafts. 
